DXCM - DexCom, Inc. Последние новости | Finranks

16.06.2026

DXCM Receives FDA Clearance for Stelo OTC CGM System for Children

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

16.06.2026

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

12.06.2026

FDA clears first over-the-counter glucose monitor for children

The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor ‌System to children with diabetes, making it the first over-the-counter continuous glucose monitor for pediatric use.

11.06.2026

Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction

Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been ‌slated for destruction, after the device maker warned some units were stolen during disposal and resold.

10.06.2026

Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

08.06.2026

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

08.06.2026

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

Видео

19.02.2026

Positive

The Big 3: VZ, DXCM, AMAT

13.01.2026

Neutral

Watch CNBC's exclusive interview with Dexcom CEO Jake Leach

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
DXCM	Evercore ISI	In-line	undefined >> $68	November 25th 2025
DXCM	Stifel	Buy	undefined >> $85	October 21st 2025
DXCM	Oppenheimer	Perform	undefined >> undefined	September 8th 2025
DXCM	Argus	Buy	undefined >> $100	August 21st 2025
DXCM	Truist	Buy	undefined >> $102	June 16th 2025
DXCM	Goldman	Buy	undefined >> $104	May 30th 2025

Пресс-релизы

06.06.2026

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of.

DexCom, Inc. (DXCM)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты